Get the Stockscreener App
2.09
0.97%
0.02
After Hours:
2.07
-0.02
-0.96%
Neumora Therapeutics Inc stock is traded at $2.09, with a volume of 616.96K.
It is up +0.97% in the last 24 hours and down -26.92% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$2.07
Open:
$2.08
24h Volume:
616.96K
Relative Volume:
0.40
Market Cap:
$355.17M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.8246
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-5.86%
1M Performance:
-26.92%
6M Performance:
+132.79%
1Y Performance:
-80.25%
1-Day Range:
$1.97
$2.1199
1-Week Range:
$1.97
$2.2495
52-Week Range:
$0.611
$11.57
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.09 | 351.77M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
MACD Signal: Can Neumora Therapeutics Inc stock beat market expectations this quarterJuly 2025 Update & Verified Chart Pattern Signals - BỘ NỘI VỤ
Can Neumora Therapeutics Inc. stock weather global recession2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
How Neumora Therapeutics Inc. stock reacts to job market dataQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is Neumora Therapeutics Inc. stock attractive for ETFsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
What momentum indicators show for Neumora Therapeutics Inc. stockGold Moves & Safe Capital Investment Plans - Newser
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset - MSN
Neumora Therapeutics (NMRA) Stock Analysis Report | Financials & Insights - Benzinga
Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential - Investing.com Canada
Neumora Therapeutics Shares Rise After RBC Upgrade - marketscreener.com
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset (NMRA:NASDAQ) - Seeking Alpha
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline - Benzinga
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
RBC Capital Upgrades Neumora Therapeutics (NMRA) - Nasdaq
RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk - marketscreener.com
Can Neumora Therapeutics Inc. stock beat market expectations this quarterWeekly Market Report & Low Risk Profit Maximizing Plans - moha.gov.vn
What drives Neumora Therapeutics Inc stock priceIPO Market Watch & Outstanding Portfolio Tips - earlytimes.in
Neumora Therapeutics (NMRA) Price Target Increased by 21.43% to 8.67 - MSN
AlphaCore Capital LLC Invests $248,000 in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Neumora Therapeutics thanks stakeholders for supporting brain disease therapy mission - Traders Union
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Neumora Issues Shares Following Loan Conversion Notice - MSN
FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
How Neumora Therapeutics Inc. stock trades before earningsPortfolio Update Report & Weekly Setup with ROI Potential - newser.com
How Neumora Therapeutics Inc. stock reacts to oil pricesJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Is Neumora Therapeutics Inc. stock oversold or undervalued2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Chart overlay techniques for tracking Neumora Therapeutics Inc.Trade Entry Summary & Proven Capital Preservation Methods - newser.com
Neumora Therapeutics price target raised to $3 from $2 at Stifel - MSN
What momentum shifts mean for Neumora Therapeutics Inc.Quarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Can Neumora Therapeutics Inc. stock maintain growth trajectoryGlobal Markets & Accurate Trade Setup Notifications - newser.com
How to build a custom watchlist for Neumora Therapeutics Inc.Weekly Stock Summary & Daily Volume Surge Signals - newser.com
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsIndex Update & Risk Controlled Daily Trade Plans - newser.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com India
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):